Angle PLC is looking to offer a more complete, end-to-end liquid biopsy solution – from circulating tumor cell (CTC) capture to downstream analysis of these target cells – following an agreement to acquire Axela Inc., a specialist in gene expression measurement.
Angle's Parsortix system, which is CE marked for clinical use and is currently being trialed in several studies for different...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?